As filed with the Securities and Exchange Commission
on March 1, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
VYNE Therapeutics Inc.
(Exact name of registrant as specified in its
charter)
| Delaware |
|
45-3757789 |
|
(State or other jurisdiction of
incorporation or organization) |
|
(I.R.S. employer
identification no.) |
| |
|
|
685 Route 202/206 N., Suite 301
Bridgewater, New Jersey |
|
08807 |
| (Address of principal executive offices) |
|
(Zip code) |
VYNE Therapeutics Inc. 2024 Inducement Plan
(Full title of plan)
Mutya Harsch
Chief Legal Officer and General Counsel
VYNE Therapeutics Inc.
685 Route 202/206 N., Suite 301
Bridgewater, New Jersey 08807
(800) 775-7936
(Name, address, including zip code, and telephone
number, including area code, of agent for service)
Copies to:
Brian F. Leaf
Mark Ballantyne
Cooley LLP
One Freedom Square, Reston Town Center
11951 Freedom Drive
Reston, VA 20190
(703) 456-8000
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of
“large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth
company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer |
¨ |
|
Accelerated filer |
¨ |
| |
|
|
|
| Non-accelerated filer |
x |
|
Smaller reporting company |
x |
| |
|
|
|
| |
|
|
Emerging growth company |
¨ |
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
PART I
INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS
| Item 1. |
Plan Information. |
The documents containing the information specified in Part I will
be delivered in accordance with Rule 428(b) under the Securities Act of 1933, as amended (the “Securities Act”).
Such documents are not required to be, and are not, filed with the Securities and Exchange Commission (the “Commission”),
either as part of this registration statement on Form S-8 (the “Registration Statement”) or as prospectuses
or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents, and the documents incorporated by reference
under this Registration Statement pursuant to Item 3 of Part II of the Form S-8, taken together, constitute a prospectus that
meets the requirements of Section 10(a) of the Securities Act.
| Item 2. |
Registrant Information and Employee Plan Annual Information. |
The written statement required by Item 2 of Part I is included
in documents that will be delivered to participants in the plans covered by this Registration Statement pursuant to Rule 428(b) of
the Securities Act.
PART II
INFORMATION REQUIRED IN REGISTRATION STATEMENT
| Item 3. |
Incorporation of Documents by Reference. |
The following documents filed by VYNE Therapeutics Inc. (the “Registrant”)
with the Commission are incorporated by reference into this Registration Statement:
| 3. | The description of the Registrant’s common stock set forth in the Registrant’s registration statement on Form 8-A filed with the Commission on January 19, 2018, including any amendments or reports filed for the purposes of updating this description,
including Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023;
and |
| 4. | All documents, reports and definitive proxy or information statements filed by the Registrant pursuant to Sections 13(a), 13(c), 14
and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (other than Current Reports
furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the
date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates
that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated
by reference in this Registration Statement and to be part hereof from the date of filing of such documents. |
Any statement contained in a document incorporated or deemed to be
incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent
that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies
or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to
constitute a part of this Registration Statement.
| Item 4. |
Description of Securities. |
Not applicable.
| Item 5. |
Interests of Named Experts and Counsel. |
Not applicable.
| Item 6. |
Indemnification of Directors and Officers. |
As permitted by Section 102 of the Delaware General Corporation
Law, the Registrant’s amended and restated certificate of incorporation and bylaws limit or eliminate the personal liability of
each of its directors for a breach of his or her fiduciary duty of care as a director. The duty of care generally requires that, when
acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available
to them. Consequently, a director will not be personally liable to the Registrant or its stockholders for monetary damages for breach
of fiduciary duty as a director, except for liability for:
| · | any breach of the director’s duty of loyalty to the Registrant or its stockholders; |
| · | any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; |
| · | any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or |
| · | any transaction from which the director derived an improper personal benefit. |
These limitations of liability do not
affect the availability of equitable remedies such as injunctive relief or rescission. The Registrant’s amended and restated certificate
of incorporation also authorizes it to indemnify its officers, directors and other agents to the fullest extent permitted under Delaware
law.
As permitted by Section 145 of the Delaware General Corporation
Law, the Registrant’s amended and restated bylaws provide that:
| · | the Registrant shall indemnify its directors and officers, and may indemnify its employees or agents to the fullest extent permitted
by the Delaware General Corporation Law, subject to limited exceptions; |
| · | the Registrant shall advance expenses to its directors and officers, and may advance expenses to its employees and agents in connection
with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and |
| · | the rights provided in the Registrant’s amended and restated bylaws are not exclusive. |
The Registrant’s amended and restated certificate of incorporation,
as amended to date, and its amended and restated bylaws, in each case attached as exhibits to this Registration Statement, provide for
the indemnification provisions described above and elsewhere herein. The Registrant has entered into separate indemnification agreements
with its directors and officers which may be broader than the specific indemnification provisions contained in the Delaware General Corporation
Law. These indemnification agreements generally require the Registrant, among other things, to indemnify its officers and directors against
liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from unlawful
conduct. These indemnification agreements also generally require the Registrant to advance any expenses incurred by the directors or officers
as a result of any proceeding against them as to which they could be indemnified. In addition, the Registrant has purchased a policy of
directors’ and officers’ liability insurance that insures its directors and officers against the cost of defense, settlement
or payment of a judgment in some circumstances. These indemnification provisions and the indemnification agreements may be sufficiently
broad to permit indemnification of the Registrant’s officers and directors for liabilities, including reimbursement of expenses
incurred, arising under the Securities Act.
| Item 7. |
Exemption from Registration Claimed. |
Not applicable.
The undersigned Registrant hereby undertakes:
(a) To file, during any period in which offers or sales are being
made, a post-effective amendment to this Registration Statement:
| i. | To include any prospectus required by Section 10(a)(3) of the Securities Act; |
| ii. | To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth
in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar
value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate,
the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the filing fee
table filed with the effective Registration Statement; and |
| iii. | To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement
or any material change to such information in the Registration Statement; |
Provided,
however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13
or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.
(b) That for the purpose of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of the offering.
The undersigned Registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or
Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant
to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.
Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, the Registrant
has been advised that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by
the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of
any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,
the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed
by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused
this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bridgewater, State
of New Jersey, on March 1, 2024.
| VYNE Therapeutics Inc. |
|
| |
|
|
| By: |
/s/ David Domzalski |
|
| |
David Domzalski |
|
| |
Chief Executive Officer |
|
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each person whose signature appears
below constitutes and appoints David Domzalski, Tyler Zeronda and Mutya Harsch, and each of them, as such person’s true and lawful
attorneys-in-fact and agents, with full power of substitution, for such person, and in such person’s name, place and stead, in any
and all capacities to sign any or all amendments or post-effective amendments to this Registration Statement, and to file the same, with
all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents
full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises,
as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact
and agents, or any of them or their substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration
Statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature |
|
Title |
|
Date |
| |
|
|
|
/s/ David Domzalski
David Domzalski |
|
Director and Chief Executive Officer
(Principal Executive Officer) |
|
March 1, 2024 |
| |
|
|
|
/s/ Tyler Zeronda
Tyler Zeronda |
|
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer) |
|
March 1, 2024 |
| |
|
|
|
/s/ Sharon Barbari
Sharon Barbari |
|
Director |
|
March 1, 2024 |
| |
|
|
|
/s/ Steven Basta
Steven Basta |
|
Director |
|
March 1, 2024 |
| |
|
|
|
|
|
/s/ Christine
Borowski
Christine Borowski |
|
Director |
|
March 1, 2024 |
| |
|
|
|
/s/ Anthony
Bruno
Anthony Bruno |
|
Director |
|
March 1, 2024 |
| |
|
|
|
/s/ Patrick
LePore
Patrick LePore |
|
Director |
|
March 1, 2024 |
| |
|
|
|
/s/ Elisabeth
Sandoval Little
Elisabeth Sandoval Little |
|
Director |
|
March 1, 2024 |
Exhibit 4.4
VYNE
THERAPEUTICS INC.
2024
INDUCEMENT PLAN
1. General.
(a) Eligible
Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards
for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under
Nasdaq IM 5635-1. A person who previously served as an Employee or Director will not be eligible to receive Awards under the Plan, other
than following a bona fide period of non-employment. Persons eligible to receive grants of Awards under this Plan are referred
to in this Plan as “Eligible Employees.” These Awards must be approved by either a majority of the Company’s
“Independent Directors” (as such term is defined in Nasdaq Marketplace Rule 5605(a)(2)) (“Independent Directors”)
or the Company’s compensation committee, provided such committee is comprised solely of Independent Directors of the Company (the
“Independent Compensation Committee”) in order to comply with the exemption from the stockholder approval requirement
for “inducement grants” provided under Rule 5635(c)(4) of the Nasdaq Marketplace Rules. Nasdaq Marketplace Rule 5635(c)(4) and
the related guidance under Nasdaq IM 5635-1 (together with any analogous rules or guidance effective after the date hereof, the “Inducement
Award Rules”).
(b) Available
Awards. The Plan provides for the grant of the following Awards: (i) Nonstatutory Share Options, (ii) Share Appreciation
Rights, (iii) Restricted Share Awards, (iv) Restricted Share Unit Awards, (v) Performance Share Awards, (vi) Performance
Cash Awards, and (vii) Other Share Awards.
(c) Purpose.
The Plan, through the grant of Awards, is intended to (i) provide a material inducement for certain individuals to enter into employment
with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Marketplace Rules, (ii) help the Company secure and
retain the services of Eligible Employees, (iii) provide incentives for such persons to exert maximum efforts for the success of
the Company and any Affiliate, and (iv) provide a means by which such persons may benefit from increases in value of the Shares.
2. Administration.
(a) Administration
by Board. The Board will administer the Plan; provided, however, that Awards may only be granted by either (i) a majority of
the Company’s Independent Directors or (ii) the Independent Compensation Committee. Subject to those constraints and the other
constraints of the Inducement Award Rules, the Board may delegate administration of the Plan as provided in Section 2(e).
(b) Eligible
Award Recipients. Awards may only be granted to persons who are Eligible Employees described in Section 1(a) of the Plan,
where the Award is an inducement material to the individual’s entering into employment with the Company or an Affiliate within the
meaning of Rule 5635(c)(4) of the Nasdaq Marketplace Rules or is otherwise permitted pursuant to Rule 5635(c) of
the Nasdaq Marketplace Rules.
(c) Approval
Requirements. All Awards must be granted either by a majority of the Company’s Independent Directors or by the Independent Compensation
Committee.
(d) Powers
of Board. The Board will have the power, subject to and within the limitations of, the express provisions of the Plan and the Inducement
Plan Rules:
(i) To
determine: (A) who will be granted Awards; (B) when and how each Award will be granted; (C) what type of Award will be
granted; (D) the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or
otherwise receive cash or Shares under the Award; (E) the number of Shares subject to, or the cash value of, an Award; and (F) the
Fair Market Value applicable to a Share Award; provided, however, that Awards may only be granted by either (i) a majority of the
Company’s Independent Directors or (ii) the Independent Compensation Committee.
(ii) To
construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for administration
of the Plan and Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in
any Award Agreement or in the written terms of a Performance Cash Award, in a manner and to the extent it will deem necessary or expedient
to make the Plan or Award fully effective.
(iii) To
settle all controversies regarding the Plan and Awards granted under it.
(iv) To
accelerate, in whole or in part, the time at which an Award may be exercised or vest (or the time at which cash or Shares may be issued
in settlement thereof).
(v) To
suspend or terminate the Plan at any time. Except as otherwise provided in the Plan or an Award Agreement, suspension or termination of
the Plan will not materially impair a Participant’s rights under the Participant’s then-outstanding Award without the Participant’s
written consent, except as provided in subsection (viii) below.
(vi) To
amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to
certain nonqualified deferred compensation under Section 409A of the Code and/or ensuring that Awards are exempt from, or compliant
with, the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any,
of Applicable Law. Except as otherwise provided in the Plan or an Award Agreement, no amendment of the Plan will materially impair a Participant’s
rights under an outstanding Award without the Participant’s written consent.
(vii) To
the extent required by Applicable Law, to submit amendments to the Plan for shareholder approval.
(viii) To
approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited
to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified
limits in the Plan that are not subject to Board discretion (including, without limitation, the limits set forth in Sections 8(c) and
8(m) below); provided, however, that a Participant’s rights under any Award will not be impaired by any such
amendment unless (A) the Company requests the consent of the affected Participant, and (B) such Participant consents in writing.
Notwithstanding the foregoing, (1) a Participant’s rights will not be deemed to have been impaired by any such amendment if
the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant’s
rights, and (2) subject to the limitations of Applicable Law, if any, the Board may amend the terms of any one or more Awards without
the affected Participant’s consent (A) to clarify the manner of exemption from, or to bring the Award into compliance with,
Section 409A of the Code; or (B) to comply with other Applicable Laws or listing requirements.
(ix) Generally,
to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company
and that are not in conflict with the provisions of the Plan or Awards.
(x) To
adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Eligible Employees who are
foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications
to the Plan or any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).
(e) Delegation
to Committee.
(i) General.
Subject to the provisions of Applicable Law and the Inducement Award Rules, the Board may delegate some or all of the administration of
the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection
with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, (and references
in this Plan to the Board will thereafter be to the Committee). Any delegation of administrative powers will be reflected in resolutions,
not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Board may retain
the authority to concurrently administer the Plan with the Committee and may, at any time, subject to the Inducement Award Rules, revest
in the Board some or all of the powers previously delegated.
(ii) Rule 16b-3
Compliance. In cases where a Committee’s actions are required to comply with Rule 16b-3, the relevant Committee shall consist
solely of two or more directors that qualify as Non-Employee Directors, in accordance with Rule 16b-3.
(f) Effect
of Board’s Decision. All determinations, interpretations and constructions made by the Board in good faith will not be subject
to review by any person and will be final, binding and conclusive on all persons.
(g) No
Repricing of Awards. Neither the Board nor any Committee will have the authority to (i) reduce the exercise or strike price of
any outstanding Option or SAR or (ii) cancel any outstanding Option or SAR that has an exercise or strike price (per share) greater
than the then-current Fair Market Value of the Shares in exchange for cash or other Share Awards under the Plan, unless the shareholders
of the Company have approved such an action within twelve (12) months prior to such an event.
3. Shares
subject to the Plan.
(a) Share
Reserve. Subject to Sections 3(b) and 9(a), a total of 500,000 Shares shall be authorized for Awards granted under the Plan (the
“Share Reserve”). The issuance of Substitute Awards will not reduce the number of Shares available for issuance
under the Plan.
(b) Reversion
of Shares to the Share Reserve. The following Shares will become available again for issuance under the Plan: (A) any Shares
subject to a Share Award that are not issued because such Share Award or any portion thereof expires or otherwise terminates without all
of the shares covered by such Share Award having been issued; (B) any Shares issued pursuant to a Share Award that are forfeited
back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such Shares;
(C) any Shares that are reacquired or withheld (or not issued) by the Company to satisfy the exercise, strike or purchase price of
a Share Award granted under the Plan (including any Shares subject to such award that are not delivered because such award is exercised
through a reduction of shares subject to such award (i.e., “net exercised”)); and (D) any Shares that are reacquired
or withheld (or not issued) by or otherwise tendered or remitted to the Company to satisfy a tax withholding obligation in connection
with a Share Award granted under the Plan.
(c) Source
of Shares. The Shares issuable under the Plan will be authorized but unissued or reacquired Shares, including Shares repurchased by
the Company on the open market or otherwise.
4. Eligibility.
Share Awards may be granted to Eligible Employees; provided, however, that Share Awards may not be granted to
Eligible Employees who are providing Continuous Service only to any “parent” of the Company, as such term is defined in Rule 405
of the Securities Act, unless (i) the Share underlying such Share Awards is treated as “service recipient share” under
Section 409A of the Code (for example, because the Share Awards are granted pursuant to a corporate transaction such as a spin off
transaction), (ii) the Company, in consultation with its legal counsel, has determined that such Share Awards are otherwise exempt
from Section 409A of the Code, or (iii) the Company, in consultation with its legal counsel, has determined that such Share
Awards comply with the distribution requirements of Section 409A of the Code.
5. Provisions
relating to Options and Share Appreciation Rights.
Each Option or SAR will be
in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be Nonstatutory Share Options.
The provisions of separate Options or SARs need not be identical; provided, however, that each Award Agreement will conform
to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the
following provisions:
(a) Term.
No Option or SAR will be exercisable after the expiration of ten years from the date of its grant or such shorter period specified in
the Award Agreement.
(b) Exercise
Price. Except in the case of Substitute Awards, the exercise or strike price of each Option or SAR will be not less than 100% of the
Fair Market Value of the Shares subject to the Option or SAR on the date the Award is granted. Notwithstanding the foregoing, an Option
or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Shares subject to the Award if
such Award is granted pursuant to an assumption of or substitution for another option or share appreciation right pursuant to a Corporate
Transaction and in a manner consistent with the provisions of Section 409A of the Code. Each SAR will be denominated in Share equivalents.
(c) Purchase
Price for Options. The purchase price of Shares acquired pursuant to the exercise of an Option may be paid, to the extent permitted
by Applicable Law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below.
Options may be granted that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods)
or that require the consent of the Company to use a particular method of payment. The permitted methods of payment are as follows:
(i) by
cash, check, bank draft or money order payable to the Company;
(ii) pursuant
to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the Share subject
to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate
exercise price to the Company from the sales proceeds;
(iii) by
delivery to the Company (either by actual delivery or attestation) of Shares;
(iv) by
a “net exercise” arrangement pursuant to which the Company will reduce the number of Shares issuable upon exercise by the
largest whole number of Shares with a Fair Market Value that does not exceed the aggregate exercise price; provided, however,
that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise
price not satisfied by such reduction in the number of whole Shares to be issued. Shares will no longer be subject to an Option and will
not be exercisable thereafter to the extent that (A) Shares issuable upon exercise are used to pay the exercise price pursuant to
the “net exercise,” (B) Shares are delivered to the Participant as a result of such exercise, and (C) Shares are
withheld to satisfy tax withholding obligations; or
(v) in
any other form of legal consideration that may be acceptable to the Board and specified in the applicable Award Agreement.
(d) Exercise
and Payment of a SAR. To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance
with the provisions of the Share Appreciation Right Agreement evidencing such SAR. The appreciation distribution payable on the exercise
of a SAR will be not greater than an amount equal to the excess of (A) the aggregate Fair Market Value (on the date of the exercise
of the SAR) of a number of Shares equal to the number of Share equivalents in which the Participant is vested under such SAR, and with
respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Share equivalents
with respect to which the Participant is exercising the SAR on such date. The appreciation distribution may be paid in Shares, in cash,
in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing
such SAR.
(e) Transferability
of Options and SARs. The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as
the Board will determine; provided, however, that in no event may Options and SARs be transferred to a third-party financial
institution. In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of
Options and SARs will apply:
(i) Restrictions
on Transfer. An Option or SAR will not be transferable except by will or by the laws of descent and distribution (or pursuant to subsections
(ii) and (iii) below), and will be exercisable during the lifetime of the Participant only by the Participant. Notwithstanding
the foregoing, the Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities
laws, including to such relatives, trusts, foundations and charities with respect to whom (or which) transfers are permitted by Applicable
Law. Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration.
(ii) Domestic
Relations Orders. Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant
to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted
by Treasury Regulations Section 1.421-1(b)(2).
(iii) Beneficiary
Designation. Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to
the Company, in a form approved by the Company (or the designated broker), designate a third party who, on the death of the Participant,
will thereafter be entitled to exercise the Option or SAR and receive the Shares or other consideration resulting from such exercise.
In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant’s estate
will be entitled to exercise the Option or SAR and receive the Shares or other consideration resulting from such exercise. However, the
Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would
be inconsistent with the provisions of Applicable Laws.
(f) Vesting
Generally. The total number of Shares subject to an Option or SAR may vest and become exercisable in periodic installments that may
or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be
exercised (which may be based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate. The vesting
provisions of individual Options or SARs may vary. The provisions of this Section 5(f) are subject to any Option or SAR provisions
governing the minimum number of Shares as to which an Option or SAR may be exercised.
(g) Termination
of Continuous Service. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and
the Company, if a Participant’s Continuous Service terminates (other than for Cause and other than upon the Participant’s
death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise
such Award as of the date of termination of Continuous Service) within the period of time ending on the earlier of (i) the date three
months following the termination of the Participant’s Continuous Service (or such longer or shorter period specified in the applicable
Award Agreement), and (ii) the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after termination
of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the
Option or SAR will terminate.
(h) Extension
of Termination Date. If the exercise of an Option or SAR following the termination of the Participant’s Continuous Service (other
than for Cause and other than upon the Participant’s death or Disability) would be prohibited at any time solely because the issuance
of Shares would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of
(i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post termination exercise period
after the termination of the Participant’s Continuous Service during which the exercise of the Option or SAR would not be in violation
of such registration requirements, and (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award
Agreement. In addition, unless otherwise provided in a Participant’s Award Agreement, if the sale of any Shares received on exercise
of an Option or SAR following the termination of the Participant’s Continuous Service (other than for Cause) would violate the Company’s
insider trading policy, then the Option or SAR will terminate on the earlier of (i) the expiration of a period of months (that need
not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant’s Continuous
Service during which the sale of the Shares received upon exercise of the Option or SAR would not be in violation of the Company’s
insider trading policy, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.
(i) Disability
of Participant. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the
Company, if a Participant’s Continuous Service terminates as a result of the Participant’s Disability, the Participant may
exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination
of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months following such termination
of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of
the Option or SAR as set forth in the Award Agreement. If, after termination of Continuous Service, the Participant does not exercise
his or her Option or SAR within the applicable time frame, the Option or SAR (as applicable) will terminate.
(j) Death
of Participant. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the
Company, if (i) a Participant’s Continuous Service terminates as a result of the Participant’s death, or (ii) the
Participant dies within the period (if any) specified in the Award Agreement for exercisability after the termination of the Participant’s
Continuous Service for a reason other than death, then the Option or SAR may be exercised (to the extent the Participant was entitled
to exercise such Option or SAR as of the date of death) by the Participant’s estate, by a person who acquired the right to exercise
the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant’s death,
but only within the period ending on the earlier of (i) the date 12 months following the date of death (or such longer or shorter
period specified in the Award Agreement), and (ii) the expiration of the term of such Option or SAR as set forth in the Award Agreement.
If, after the Participant’s death, the Option or SAR is not exercised within the applicable time frame, the Option or SAR (as applicable)
will terminate.
(k) Termination
for Cause. Except as explicitly provided otherwise in a Participant’s Award Agreement or other individual written agreement
between the Company or any Affiliate and the Participant, if a Participant’s Continuous Service is terminated for Cause, the Option
or SAR will terminate immediately upon such Participant’s termination of Continuous Service, and the Participant will be prohibited
from exercising his or her Option or SAR from and after the time of such termination of Continuous Service.
(l) Non-Exempt
Employees. If an Option or SAR is granted to an Eligible Employee who is a non-exempt employee for purposes of the Fair Labor Standards
Act of 1938, as amended, the Option or SAR will not be first exercisable for any Shares until at least six months following the date of
grant of the Option or SAR (although the Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity
Act, (i) if such non-exempt Employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such Option or
SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the Participant’s retirement
(as such term may be defined in the Participant’s Award Agreement in another agreement between the Participant and the Company,
or, if no such definition, in accordance with the Company’s then current employment policies and guidelines), the vested portion
of any Options and SARs may be exercised earlier than six months following the date of grant. The foregoing provision is intended to operate
so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from
his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure
that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any Shares under any other Share
Award will be exempt from the employee’s regular rate of pay, the provisions of this Section 5(l) will apply to all Share
Awards and are hereby incorporated by reference into such Share Award Agreements.
6. Provisions
of Share Awards other than Options and SARS.
(a) Restricted
Share Awards. Each Restricted Share Award Agreement will be in such form and will contain such terms and conditions as the Board will
deem appropriate. To the extent consistent with the Company’s Articles of Association, at the Board’s election, Shares may
be (x) held in book entry form subject to the Company’s instructions until any restrictions relating to the Restricted Share
Award lapse; or (y) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board.
The terms and conditions of Restricted Share Award Agreements may change from time to time, and the terms and conditions of separate Restricted
Share Award Agreements need not be identical. Each Restricted Share Award Agreement will conform to (through incorporation of the provisions
hereof by reference in the agreement or otherwise) the substance of each of the following provisions:
(i) Consideration.
A Restricted Share Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company, (B) past
services to the Company or an Affiliate, or (C) any other form of legal consideration that may be acceptable to the Board, in its
sole discretion, and permissible under Applicable Law.
(ii) Vesting.
Shares awarded under the Restricted Share Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule
to be determined by the Board.
(iii) Termination
of Participant’s Continuous Service. If a Participant’s Continuous Service terminates, the Company may receive through
a forfeiture condition or a repurchase right any or all of the Shares held by the Participant that have not vested as of the date of termination
of Continuous Service under the terms of the Restricted Share Award Agreement.
(iv) Transferability.
Rights to acquire Shares under the Restricted Share Award Agreement will be transferable by the Participant only upon such terms and conditions
as are set forth in the Restricted Share Award Agreement, as the Board will determine in its sole discretion, so long as Shares awarded
under the Restricted Share Award Agreement remains subject to the terms of the Restricted Share Award Agreement.
(b) Restricted
Share Unit Awards. Each Restricted Share Unit Award Agreement will be in such form and will contain such terms and conditions as the
Board will deem appropriate. The terms and conditions of Restricted Share Unit Award Agreements may change from time to time, and the
terms and conditions of separate Restricted Share Unit Award Agreements need not be identical. Each Restricted Share Unit Award Agreement
will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the
following provisions:
(i) Consideration.
At the time of grant of a Restricted Share Unit Award, the Board will determine the consideration, if any, to be paid by the Participant
upon delivery of each Share subject to the Restricted Share Unit Award. The consideration to be paid (if any) by the Participant for each
Share subject to a Restricted Share Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in
its sole discretion, and permissible under Applicable Law.
(ii) Vesting.
At the time of the grant of a Restricted Share Unit Award, the Board may impose such restrictions on or conditions to the vesting of the
Restricted Share Unit Award as it, in its sole discretion, deems appropriate.
(iii) Payment.
A Restricted Share Unit Award may be settled by the delivery of Shares, their cash equivalent, any combination thereof or in any other
form of consideration, as determined by the Board and contained in the Restricted Share Unit Award Agreement.
(iv) Additional
Restrictions. At the time of the grant of a Restricted Share Unit Award, the Board, as it deems appropriate, may impose such restrictions
or conditions that delay the delivery of the Shares (or their cash equivalent) subject to a Restricted Share Unit Award to a time after
the vesting of such Restricted Share Unit Award.
(v) Termination
of Participant’s Continuous Service. Except as otherwise provided in the applicable Restricted Share Unit Award Agreement, such
portion of the Restricted Share Unit Award that has not vested will be forfeited upon the Participant’s termination of Continuous
Service.
(c) Performance
Awards.
(i) Performance
Share Awards. A Performance Share Award is a Share Award that is payable (including that may be granted, may vest or may be exercised)
contingent upon the attainment during a Performance Period of certain Performance Goals. A Performance Share Award may, but need not,
require the Participant’s completion of a specified period of Continuous Service. The length of any Performance Period, the Performance
Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained
will be conclusively determined by the Board or the Committee, in its sole discretion. In addition, to the extent permitted by Applicable
Law and the applicable Award Agreement, the Board or the Committee may determine that cash may be used in payment of Performance Share
Awards.
(ii) Performance
Cash Awards. A Performance Cash Award is a cash award that is payable contingent upon the attainment during a Performance Period of
certain Performance Goals. A Performance Cash Award may also require the completion of a specified period of Continuous Service. At the
time of grant of a Performance Cash Award, the length of any Performance Period, the Performance Goals to be achieved during the Performance
Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the
Board or the Committee, in its sole discretion. The Board or the Committee may specify the form of payment of Performance Cash Awards,
which may be cash or other property, or may provide for a Participant to have the option for his or her Performance Cash Award, or such
portion thereof as the Board or the Committee may specify, to be paid in whole or in part in cash or other property.
(d) Other
Share Awards. Other forms of Share Awards valued in whole or in part by reference to, or otherwise based on, Shares, including the
appreciation in value thereof may be granted either alone or in addition to Share Awards provided for under Section 5 and the preceding
provisions of this Section 6. Subject to the provisions of the Plan, the Board will have sole and complete authority to determine
the persons to whom and the time or times at which such Other Share Awards will be granted, the number of Shares (or the cash equivalent
thereof) to be granted pursuant to such Other Share Awards and all other terms and conditions of such Other Share Awards.
7. Covenants
of the Company.
(a) Availability
of Shares. The Company will keep available at all times the number of Shares reasonably required to satisfy then-outstanding Awards.
(b) Securities
Law Compliance. The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority
as may be required to grant Share Awards and to issue and sell Shares upon exercise of the Share Awards; provided, however,
that this undertaking will not require the Company to register under the Securities Act the Plan, any Share Award or any Shares issued
or issuable pursuant to any such Share Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from
any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of
Shares under the Plan, the Company will be relieved from any liability for failure to issue and sell Shares upon exercise of such Share
Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of an Award or the subsequent issuance
of cash or Shares pursuant to the Award if such grant or issuance would be in violation of any applicable securities law.
(c) No
Obligation to Notify or Minimize Taxes. The Company will have no duty or obligation to any Participant to advise such holder as to
the time or manner of exercising such Share Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise
such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company
has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award.
8. Miscellaneous.
(a) Use
of Proceeds from Sales of Shares. Proceeds from the sale of Shares pursuant to Awards will constitute general funds of the Company.
(b) Corporate
Action Constituting Grant of Awards. Corporate action constituting a grant by the Company of an Award to any Participant will be deemed
completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate,
or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate
records (e.g., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (e.g., exercise
price, vesting schedule or number of Shares) that are inconsistent with those in the Award Agreement or related grant documents as a result
of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will control and the Participant
will have no legally binding right to the incorrect term in the Award Agreement or related grant documents.
(c) Shareholder
Rights. No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any Shares subject
to an Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of Shares under,
the Award pursuant to its terms, and (ii) the issuance of the Shares subject to such Award has been entered into the books and records
of the Company.
(d) No
Employment or Other Service Rights. Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection
with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in
the capacity in effect at the time the Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the
employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms
of such Consultant’s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the Articles
of Association of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or
the Affiliate is incorporated, as the case may be.
(e) Change
in Time Commitment. In the event a Participant’s regular level of time commitment in the performance of his or her services
for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and
the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the
date of grant of any Award to the Participant, the Board has the right in its sole discretion to (x) make a corresponding reduction
in the number of Shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date
of such change in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting or payment schedule
applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award
that is so reduced or extended.
(f) Investment
Assurances. The Company may require a Participant, as a condition of exercising or acquiring Shares under any Award, (i) to give
written assurances satisfactory to the Company as to the Participant’s knowledge and experience in financial and business matters
and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and
business matters and that such Participant is capable of evaluating, alone or together with the purchaser representative, the merits and
risks of exercising the Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring
Shares subject to the Award for the Participant’s own account and not with any present intention of selling or otherwise distributing
the Shares. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A) the issuance
of the Shares upon the exercise or acquisition of Shares under the Award has been registered under a then currently effective registration
statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that
such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel
to the Company, place legends on Share certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply
with applicable securities laws, including, but not limited to, legends restricting the transfer of the Shares.
(g) Withholding
Obligations. Unless prohibited by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any federal, state
or local tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing
the Participant to tender a cash payment; (ii) withholding Shares from the Shares issued or otherwise issuable to the Participant
in connection with the Award; provided, however, that no Shares are withheld with a value exceeding an amount of tax calculated
based on the maximum statutory tax rates in a Participant’s applicable tax jurisdiction (or such other amount as may be necessary
to avoid classification of the Share Award as a liability for financial accounting purposes); (iii) withholding cash from an Award
settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; (v) a “sell to cover”
arrangement; or (vi) by such other method as may be set forth in the Award Agreement.
(h) Electronic
Delivery. Any reference herein to a “written” agreement or document will include any agreement or document delivered electronically,
filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company’s intranet (or other shared electronic
medium controlled by the Company to which the Participant has access).
(i) Deferrals.
To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that the delivery of Shares or the payment
of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures
for deferral elections to be made by Participants. Deferrals by Participants will be made in accordance with Section 409A of the
Code. Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee
or otherwise providing services to the Company. The Board is authorized to make deferrals of Awards and determine when, and in what annual
percentages, Participants may receive payments, including lump sum payments, following the Participant’s termination of Continuous
Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with Applicable Law.
(j) Compliance
with Section 409A of the Code. Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will
be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A
of the Code, and, to the extent not so exempt, in compliance with Section 409A of the Code. If the Board determines that any Award
granted hereunder is not exempt from and is therefore subject to Section 409A of the Code, the Award Agreement evidencing such Award
will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and
to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the
Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise),
if the Shares are publicly traded, and if a Participant holding an Award that constitutes “deferred compensation” under Section 409A
of the Code is a “specified employee” for purposes of Section 409A of the Code, no distribution or payment of any amount
that is due because of a “separation from service” (as defined in Section 409A of the Code without regard to alternative
definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant’s “separation
from service” (as defined in Section 409A of the Code without regard to alternative definitions thereunder) or, if earlier,
the date of the Participant’s death, unless such distribution or payment can be made in a manner that complies with Section 409A
of the Code, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid
thereafter on the original schedule.
(k) Clawback/Recovery.
All Awards granted under the Plan will be subject to recoupment in accordance with the Company’s current clawback policies, as they
may be amended from time to time, including the clawback policy that the Company adopted in November 2023 as required by the Dodd-Frank
Wall Street Reform and Consumer Protection Act and related stock exchange listing standards. In addition, the Board may impose such other
clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not
limited to a reacquisition right in respect of previously acquired Shares or other cash or property upon the occurrence of an event constituting
Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for “good reason”
or “constructive termination” (or similar term) under any agreement with the Company.
(l) Dividends
and Dividend Equivalents. Dividends and dividend equivalents may be credited in respect of Shares covered by a Share Award (other
than Options and Share Appreciation Rights), as determined by the Board and contained in the applicable Award Agreement. For the avoidance
of doubt, dividends and dividend equivalents may not be credited or paid in respect of Shares covered by an Option or Share Appreciation
Right. At the sole discretion of the Board, such dividends and dividend equivalents may be converted into additional Shares covered by
the Share Award in such manner as determined by the Board. Any additional Shares or cash payments covered by the Share Award credited
by reason of such dividends or dividend equivalents will be subject to all of the same terms and conditions of the underlying Award Agreement
to which they relate. Notwithstanding anything to the contrary in this Plan or any Award Agreement, dividends and dividend equivalents
shall not be paid in respect of Shares covered by a Share Award until such Shares vest pursuant to the applicable Award Agreement.
(m) Rules Applicable
to Specific Countries. Notwithstanding anything herein to the contrary, the terms and conditions of the Plan may be adjusted with
respect to a particular country by means of an addendum to the Plan in the form of an annex, and to the extent that the terms and conditions
set forth in such annex conflict with any provisions of the Plan, the provisions of the annex shall govern unless impermissible under
Applicable Law. The adoption of any such annex shall be subject to the approval of the Board.
9. Adjustments
upon changes in Shares; other Corporate Events.
(a) Capitalization
Adjustments. In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es)
and maximum number of securities subject to the Plan pursuant to Section 3(a) and (ii) the class(es) and number of securities
and price per share of share subject to outstanding Share Awards. The Board will make such adjustments, and its determination will be
final, binding and conclusive.
(b) Dissolution.
Except as otherwise provided in the Share Award Agreement, in the event of a Dissolution of the Company, all outstanding Share Awards
(other than Share Awards consisting of vested and outstanding Shares not subject to a forfeiture condition or the Company’s right
of repurchase) will terminate immediately prior to the completion of such Dissolution, and the Shares subject to the Company’s repurchase
rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of
such Share Award is providing Continuous Service; provided, however, that the Board may, in its sole discretion, cause some
or all Share Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Share
Awards have not previously expired or terminated) before the Dissolution is completed but contingent on its completion.
(c) Transactions.
The following provisions shall apply to Awards in the event of a Transaction unless otherwise provided in the instrument evidencing
the Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided
by the Board at the time of grant of an Award.
(i) Awards
May Be Assumed. In the event of a Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring
corporation’s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar awards
for Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders
of the Company pursuant to the Transaction), and any reacquisition or repurchase rights held by the Company in respect of Shares issued
pursuant to Share Awards may be assigned by the Company to the successor of the Company (or the successor’s parent company, if any),
in connection with such Transaction. A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue
only a portion of an Award or substitute a similar award for only a portion of an Award, or may choose to assume, continue, or substitute
the Share Awards held by some, but not all Participants. The terms of any assumption, continuation or substitution will be set by the
Board.
(ii) Awards
Held by Current Participants. In the event of a Transaction in which the surviving corporation or acquiring corporation (or its parent
company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect
to Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated
prior to the effective time of the Transaction (referred to as the “Current Participants”), the vesting of such Awards
(and, with respect to Options and SARs, the time when such Awards may be exercised) will be accelerated in full to a date prior to the
effective time of such Transaction (contingent upon the effectiveness of the Transaction) as the Board determines (or, if the Board does
not determine such a date, to the date that is five days prior to the effective time of the Transaction), and such Awards will terminate
if not exercised (if applicable) at or prior to the effective time of the Transaction, and any reacquisition or repurchase rights held
by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Transaction). With respect to the vesting
of Performance Awards that will accelerate upon the occurrence of a Transaction pursuant to this subsection (ii) and that have multiple
vesting levels depending on the level of performance, unless otherwise provided in the Award Agreement, the vesting of such Performance
Awards will accelerate at 100% of the target level upon the occurrence of the Transaction. With respect to the vesting of Awards that
will accelerate upon the occurrence of a Transaction pursuant to this subsection (ii) and are settled in the form of a cash payment,
such cash payment will be made no later than 30 days following the occurrence of the Transaction.
(iii) Awards
Held by Persons other than Current Participants. In the event of a Transaction in which the surviving corporation or acquiring corporation
(or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards,
then with respect to Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants,
such Awards will terminate if not exercised (if applicable) prior to the occurrence of the Transaction; provided, however, that any reacquisition
or repurchase rights held by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding
the Transaction.
(iv) Payment
for Awards in Lieu of Exercise. Notwithstanding the foregoing, in the event an Award will terminate if not exercised prior to the
effective time of a Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not exercise such Award
but will receive a payment, in such form as may be determined by the Board, equal in value, at the effective time, to the excess, if any,
of (1) the value of the property the Participant would have received upon the exercise of the Award (including, at the discretion
of the Board, any unvested portion of such Award), over (2) any exercise price payable by such holder in connection with such exercise.
(d) Appointment
of Stockholder Representative. As a condition to the receipt of an Award under this Plan, a Participant will be deemed to have agreed
that the Award will be subject to the terms of any agreement governing a Transaction involving the Company, including, without limitation,
a provision for the appointment of a stockholder representative that is authorized to act on the Participant’s behalf with respect
to any escrow, indemnities and any contingent consideration.
(e) No
Restriction on Right to Undertake Transactions. The grant of any Award under the Plan and the issuance of shares pursuant to any Award
does not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize any adjustment,
recapitalization, reorganization or other change in the Company’s capital structure or its business, any merger or consolidation
of the Company, any issue of stock or of options, rights or options to purchase stock or of bonds, debentures, preferred or prior preference
stocks whose rights are superior to or affect the Shares or the rights thereof or which are convertible into or exchangeable for Shares,
or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate
act or proceeding, whether of a similar character or otherwise.
10. Earlier
Termination or Suspension of the Plan.
The Board may suspend or terminate
the Plan at any time. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. Suspension or termination
of the Plan will not impair rights and obligations under any Award granted while the Plan is in effect except with the written consent
of the affected Participant or as otherwise permitted in the Plan.
11. Existence
of the Plan.
The Plan became effective
on the Effective Date.
12. Choice
of Law.
The laws of the State of Delaware
will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state’s
conflict of laws rules.
13. Definitions.
As used in the Plan, the following definitions will apply to the capitalized terms indicated below:
(a) “Affiliate”
means, at the time of determination, any “parent” or “subsidiary” of the Company as such terms are defined in
Rule 405 of the Securities Act. The Board will have the authority to determine the time or times at which “parent” or
“subsidiary” status is determined within the foregoing definition.
(b) “Applicable
Law” means the legal requirements applicable to the administration of equity incentive plans, any applicable laws, rules and
regulations in Israel and in any country or jurisdiction where Awards are granted under the Plan, as such laws, rules, regulations and
requirements shall be in place from time to time including any Stock Exchange rules or regulations;
(c) “Award”
means a Share Award or a Performance Cash Award.
(d) “Award
Agreement” means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.
(e) “Board”
means the Board of Directors of the Company.
(f) “Capital
Shares” means each and every class of shares of the Company, regardless of the number of votes per share.
(g) “Capitalization
Adjustment” means any change that is made in, or other events that occur with respect to, the Shares subject to the Plan
or subject to any Share Award without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization,
reincorporation, share dividend, dividend in property other than cash, large nonrecurring cash dividend, share split, reverse share split,
liquidating dividend, combination of shares, exchange of shares, spin-off, change in corporate structure or any similar equity restructuring
transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or
any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated
as a Capitalization Adjustment.
(h) “Cause”
shall have the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and,
in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i) such
Participant’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United
States or any state thereof; (ii) such Participant’s attempted commission of, or participation in, a fraud or act of dishonesty
against the Company; (iii) such Participant’s intentional, material violation of any contract or agreement between the Participant
and the Company or of any statutory duty owed to the Company; (iv) such Participant’s unauthorized use or disclosure of the
Company’s confidential information or trade secrets; (v) such Participant’s gross misconduct; (vi) the Participant’s
willful and continued failure to substantially perform the Participant’s duties; or (vi) other conduct by the Participant that
could be expected to be harmful to the business, interests or reputation of the Company. The determination that a termination of the Participant’s
Continuous Service is either for Cause or without Cause shall be made by the Company, in its sole discretion Any determination by the
Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held
by such Participant shall have no effect upon any determination of the rights or obligations of the Company or such Participant for any
other purpose.
(i) “Change
in Control” means the occurrence, in a single transaction or in a series of related transactions, of any one or more of
the following events:
(i) any
Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined
voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction.
Notwithstanding the foregoing, a Change in Control will not be deemed to occur (A) on account of the acquisition of securities of
the Company directly from the Company; (B) on account of the acquisition of securities of the Company by an investor, any affiliate
thereof or any other Exchange Act Person that acquires the Company’s securities in a transaction or series of related transactions
the primary purpose of which is to obtain financing for the Company through the issuance of equity securities; or (C) solely because
the level of Ownership held by any Exchange Act Person (the “Subject Person”) exceeds the designated percentage
threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing
the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result
of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any
additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then
outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control will be deemed
to occur;
(ii) there
is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the
consummation of such merger, consolidation or similar transaction, the shareholders of the Company immediately prior thereto do not Own,
directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding voting power
of the surviving Entity in such merger, consolidation or similar transaction or (B) more than 50% of the combined outstanding voting
power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same
proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction;
(iii) there
is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company
and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of
the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned
by shareholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company
immediately prior to such sale, lease, license or other disposition;
(iv) the
complete dissolution or liquidation of the Company, except for a liquidation into a parent corporation;
(v) individuals
who, on the date the Plan is adopted by the Board, are members of the Board (the “Incumbent Board”) cease for
any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or
election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent
Board then still in office, such new member will, for purposes of this Plan, be considered as a member of the Incumbent Board.
Notwithstanding the foregoing
definition or any other provision of the Plan, the term Change in Control will not include a sale of assets, merger or other transaction
effected exclusively for the purpose of changing the domicile of the Company and the definition of Change in Control (or any analogous
term) in an individual written agreement between the Company or any Affiliate and the Participant will supersede the foregoing definition
with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous
term is set forth in such an individual written agreement, the foregoing definition will apply.
If required for compliance
with Section 409A of the Code, in no event will an event be deemed a Change in Control if such event is not also a “change
in the ownership of” the Company, a “change in the effective control of” the Company or a “change in the ownership
of a substantial portion of the assets of” the Company, each as determined under Treasury Regulations Section 1.409A-3(i)(5) (without
regard to any alternative definition thereunder).
(j) “Code”
means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.
(k) “Committee”
means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section 2(e), and
to the extent necessary to comply with the Inducement Award Rules, shall mean the Independent Compensation Committee.
(l) “Company”
means VYNE Therapeutics Inc., a Delaware corporation.
(m) “Consultant”
means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services
and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for
such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered
a “Consultant” for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan
only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company’s
securities to such person. Consultants are not eligible to receive Awards under the Plan with respect to their service in such capacity.
(n) “Continuous
Service” means that the Participant’s service with the Company or an Affiliate, whether as an Employee, Director or
Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate
as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service, provided that there is
no interruption or termination of the Participant’s service with the Company or an Affiliate, will not terminate a Participant’s
Continuous Service; provided, however, that if the Entity for which a Participant is rendering services ceases to qualify
as an Affiliate, as determined by the Board, in its sole discretion, such Participant’s Continuous Service will be considered to
have terminated on the date such Entity ceases to qualify as an Affiliate. To the extent permitted by law, the Board or the chief executive
officer of the Company, in that party’s sole discretion, may determine whether Continuous Service will be considered interrupted
in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or
any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing,
a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in
the Company’s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant,
or as otherwise required by law.
(o) “Corporate
Transaction” means the consummation, in a single transaction or in a series of related transactions, of any one or more
of the following events:
(i) a
sale or other disposition of all or substantially all, as determined by the Board, in its sole discretion, of the consolidated assets
of the Company and its Subsidiaries;
(ii) a
sale or other disposition of more than 50% of the outstanding securities of the Company;
(iii) a
merger, consolidation or similar transaction following which the Company is not the surviving corporation; or
(iv) a
merger, consolidation or similar transaction following which the Company is the surviving corporation but the Shares outstanding immediately
preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar
transaction into other property, whether in the form of securities, cash or otherwise. If required for compliance with Section 409A
of the Code, in no event will an event be deemed a Corporate Transaction if such event is not also a “change in the ownership of”
the Company, a “change in the effective control of” the Company or a “change in the ownership of a substantial portion
of the assets of” the Company, each as determined under Treasury Regulations Section 1.409A-3(i)(5) (without regard to
any alternative definition thereunder).
(p) “Director”
means a member of the Board. Directors are not eligible to receive Awards under the Plan with respect to their service in such capacity.
(q) “Disability”
means, with respect to a Participant, the inability of such Participant to engage in any substantial gainful activity by reason of any
medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to
last for a continuous period of not less than 12 months, as provided in Sections 22(e)(3) and 409A(a) (2)(c)(i) of the
Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.
(r) “Dissolution”
means when the Israeli Registrar of Companies has registered the dissolution of the Company in the Israeli Registrar of Companies. Conversion
of the Company into a Limited Liability Company (or any other pass-through entity) will not be considered a “Dissolution”
for purposes of the Plan.
(s) “Effective
Date” means February 28, 2024.
(t) “Employee”
means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services,
will not cause a Director to be considered an “Employee” for purposes of the Plan.
(u) “Entity”
means a corporation, partnership, limited liability company or other entity.
(v) “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
(w) “Exchange
Act Person” means any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of
the Exchange Act), except that “Exchange Act Person” will not include (i) the Company or any Subsidiary of the Company,
(ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities
under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities
pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the shareholders of
the Company in substantially the same proportions as their Ownership of share of the Company; or (v) any natural person, Entity or
“group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that is the Owner, directly or indirectly,
of securities of the Company representing more than 50% of the combined voting power of the Company’s then outstanding securities.
(x) “Fair
Market Value” means, as of any date, the value of the Shares determined as follows:
(i) If
the Shares are listed on any established share exchange or traded on any established market, the Fair Market Value of a Share will be,
unless otherwise determined by the Board, the closing sales price for such Share as quoted on such exchange or market (or the exchange
or market with the greatest volume of trading in the Shares) on the date of determination, as reported in a source the Board deems reliable.
(ii) Unless
otherwise provided by the Board, if there is no closing sales price for the Shares on the date of determination, then the Fair Market
Value will be the closing selling price on the last preceding date for which such quotation exists.
(iii) In
the absence of such markets for the Shares, the Fair Market Value will be determined by the Board in good faith and in a manner that complies
with Section 409A of the Code.
(y) “Non-Employee
Director” means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does
not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in
any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation
S-K promulgated pursuant to the Securities Act (“Regulation S-K”)), does not possess an interest in any other
transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship
for which disclosure would be required pursuant to Item 404(b) of Regulation S-K; or (ii) is otherwise considered a “non-employee
director” for purposes of Rule 16b-3.
(z) “Nonstatutory
Share Option” means any Option granted pursuant to Section 5 of the Plan that does not qualify as an “incentive
share option” within the meaning of Section 422 of the Code.
(aa) “Officer”
means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act.
(bb) “Option”
means a Nonstatutory Share Option to purchase Shares granted pursuant to the Plan.
(cc) “Option
Agreement” means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option
grant. Each Option Agreement will be subject to the terms and conditions of the Plan.
(dd) “Optionholder”
means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.
(ee) “Other
Share Award” means an award based in whole or in part by reference to the Shares which are granted pursuant to the terms
and conditions of Section 6(d).
(ff) “Other
Share Award Agreement” means a written agreement between the Company and a holder of an Other Share Award evidencing the
terms and conditions of an Other Share Award grant. Each Other Share Award Agreement will be subject to the terms and conditions of the
Plan.
(gg) “Own,”
“Owned,” “Owner,” “Ownership” means a person or Entity will
be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership”
of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise,
has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.
(hh) “Participant”
means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Share Award
(ii) “Performance
Award” means a Performance Cash Award or a Performance Share Award.
(jj) “Performance
Cash Award” means an award of cash granted pursuant to the terms and conditions of Section 6(c)(ii).
(kk) “Performance
Criteria” means the one or more criteria that the Board or the Committee will select for purposes of establishing the Performance
Goals for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one
of, or combination of, the following as determined by the Committee (or Board, if applicable): (i) earnings (including earnings per
share and net earnings); (ii) earnings before interest, taxes and depreciation; (iii) earnings before interest, taxes, depreciation
and amortization; (iv) earnings before interest, taxes, depreciation, amortization and legal settlements; (v) earnings before
interest, taxes, depreciation, amortization, legal settlements and other income (expense); (vi) earnings before interest, taxes,
depreciation, amortization, legal settlements, other income (expense) and share-based compensation; (vii) earnings before interest,
taxes, depreciation, amortization, legal settlements, other income (expense), share-based compensation and changes in deferred revenue;
(viii) earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense), share-based compensation,
other non-cash expenses and changes in deferred revenue; (ix) total shareholder return; (x) return on equity or average shareholder’s
equity; (xi) return on assets, investment, or capital employed; (xii) share price; (xiii) margin (including gross margin);
(xiv) income (before or after taxes); (xv) operating income; (xvi) operating income after taxes; (xvii) pre-tax profit;
(xviii) operating cash flow; (xix) sales or revenue targets; (xx) increases in revenue or product revenue; (xxi) expenses
and cost reduction goals; (xxii) improvement in or attainment of working capital levels; (xxiii) economic value added (or an
equivalent metric); (xxiv) market share; (xxv) cash flow; (xxvi) cash flow per share; (xxvii) cash balance; (xxviii) cash
burn; (xxix) cash collections; (xxx) share price performance; (xxxi) debt reduction; (xxxii) implementation or completion
of projects or processes (including, without limitation, clinical trial initiation, clinical trial enrollment and dates, clinical trial
results, regulatory filing submissions, regulatory filing acceptances, regulatory or advisory committee interactions, regulatory approvals,
and product supply); (xxxiii) shareholders’ equity; (xxxiv) capital expenditures; (xxxv) debt levels; (xxxvi) operating
profit or net operating profit; (xxxvii) workforce diversity; (xxxviii) growth of net income or operating income; (xxxix) billings;
(xl) bookings; (xli) employee retention; (xlii) initiation of studies by specific dates; (xliii) budget management; (xliv) submission
to, or approval by, a regulatory body (including, but not limited to the U.S. Food and Drug Administration) of an applicable filing or
a product; (xlv) regulatory milestones; (xlvi) progress of internal research or development programs; (xlvii) acquisition of new customers;
(xlviii) customer retention and/or repeat order rate; (xlix) improvements in sample and test processing times; (l) progress of partnered
programs; (li) partner satisfaction; (lii) timely completion of clinical trials; (liii) submission of 510(k)s or pre-market approvals
and other regulatory achievements; (liv) milestones related to research development (including, but not limited to, preclinical and clinical
studies), product development and manufacturing; (lv) expansion of sales in additional geographies or markets; (lvi) research progress,
including the development of programs; (lvii) strategic partnerships or transactions (including in-licensing and out-licensing of intellectual
property; and (lviii) other measures of performance selected by the Board or the Committee.
(ll) “Performance
Goals” means, for a Performance Period, the one or more goals established by the Board or the Committee for the Performance
Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business
units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable
companies or the performance of one or more relevant indices. The Board or the Committee is authorized to make appropriate adjustments
in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1) to exclude restructuring
and/or other nonrecurring charges; (2) to exclude exchange rate effects; (3) to exclude the effects of changes to generally
accepted accounting principles; (4) to exclude the effects of any statutory adjustments to corporate tax rates; (5) to exclude
the effects of any items that are “unusual” in nature or occur “infrequently” as determined under generally accepted
accounting principles; (6) to exclude the dilutive effects of acquisitions or joint ventures; (7) to assume that any business
divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture;
(8) to exclude the effect of any change in the outstanding shares of the Company by reason of any share dividend or split, share
repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate
change, or any distributions to common shareholders other than regular cash dividends; (9) to exclude the effects of share based
compensation and the award of bonuses under the Company’s bonus plans; (10) to exclude costs incurred in connection with potential
acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; (11) to exclude the goodwill
and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles; (12) to exclude
the effects of the timing of acceptance for review and/or approval of submissions to the U.S. Food and Drug Administration or any other
regulatory body; and (13) to make other appropriate adjustments selected by the Board or the Committee.
(mm) “Performance
Period” means the period of time selected by the Board or the Committee over which the attainment of one or more Performance
Goals will be measured for the purpose of determining a Participant’s right to and the payment of a Share Award or a Performance
Cash Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board or the Committee.
(nn) “Performance
Share Award” means a Share Award granted under the terms and conditions of Section 6(c)(i).
(oo) “Plan”
means this VYNE Therapeutics Inc. 2024 Inducement Plan.
(pp) “Restricted
Share Award” means an award of Shares which are granted pursuant to the terms and conditions of Section 6(a).
(qq) “Restricted
Share Award Agreement” means a written agreement between the Company and a holder of a Restricted Share Award evidencing
the terms and conditions of a Restricted Share Award grant. Each Restricted Share Award Agreement will be subject to the terms and conditions
of the Plan.
(rr) “Restricted
Share Unit Award” means a right to receive Shares which are granted pursuant to the terms and conditions of Section 6(b).
(ss) “Restricted
Share Unit Award Agreement” means a written agreement between the Company and a holder of a Restricted Share Unit Award
evidencing the terms and conditions of a Restricted Share Unit Award grant. Each Restricted Share Unit Award Agreement will be subject
to the terms and conditions of the Plan.
(tt) “Rule 16b-3”
means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.
(uu) “Securities
Act” means the Securities Act of 1933, as amended.
(vv) “Share”
means a share of common stock of the Company
(ww) “Share
Appreciation Right” or “SAR” means a right to receive the appreciation on Shares that are granted
pursuant to the terms and conditions of Section 5.
(xx) “Share
Appreciation Right Agreement” means a written agreement between the Company and a holder of a Share Appreciation Right evidencing
the terms and conditions of a Share Appreciation Right grant. Each Share Appreciation Right Agreement will be subject to the terms and
conditions of the Plan.
(yy) “Share
Award” means any right to receive Shares granted under the Plan, including a Nonstatutory Share Option, a Restricted Share
Award, a Restricted Share Unit Award, a Share Appreciation Right, a Performance Share Award or any Other Share Award.
(zz) “Share
Award Agreement” means a written agreement between the Company and a Participant evidencing the terms and conditions of
a Share Award grant. Each Share Award Agreement will be subject to the terms and conditions of the Plan.
(aaa) “Subsidiary”
means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding Capital Shares having ordinary
voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, share of any other
class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time,
directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company
has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.
(bbb) “Substitute
Award” means an Award issued in connection with a merger or acquisition in connection with the assumption of, or substitution
for, an existing award.
(ccc) “Transaction”
means a Corporate Transaction or Change in Control.
Exhibit 4.5
VYNE
Therapeutics Inc.
Share
Option Grant Notice
(2024 Inducement Plan)
VYNE Therapeutics Inc. (formerly Menlo Therapeutics
Inc.) (the “Company”), pursuant to its 2024 Inducement Plan (the “Plan”), hereby grants
to Optionholder an option to purchase the number of Shares set forth below. This option is subject to all of the terms and conditions
as set forth in this Share Option Grant Notice, in the Option Agreement, the Plan and the Notice of Exercise, all of which are attached
hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Option
Agreement will have the same definitions as in the Plan or the Option Agreement. If there is any conflict between the terms in this Share
Option Grant Notice and the Plan, the terms of the Plan will control.
| Optionholder: |
|
| Date of Grant: |
|
| Vesting Commencement Date: |
|
| Type of Grant: |
Nonstatutory
Share Option |
| Number of Shares Subject to Option: |
|
| Exercise Price (Per Share): |
|
| Total Exercise Price: |
|
| Expiration Date: |
|
Exercise Schedule: Same
as Vesting Schedule
Vesting Schedule:
[Insert], subject to the Optionholder’s
Continuous Service with the Company as of each such vesting date; provided however, that the options shall vest in full upon a termination
of the Optionholder’s Continuous Service (i) by the Company without Cause (as defined in the Plan) or (ii) upon
a resignation by the Optionholder for Good Reason (as defined in the applicable written agreement between the Optionholder and the Company;
provided that if no such definition is included in a written agreement between the Optionholder and the Company, “Good Reason”
shall have the meaning set forth below), in each case, within 12 months following a Change in Control.
“Good Reason” means: (i) a
material reduction in your base salary; (ii) a material reduction in your target annual bonus opportunity; (iii) a relocation
of your principal place of employment by more than twenty-five (25) miles; or (iv) an adverse change in your position, including
title, reporting relationship(s), authority, duties or responsibilities; all of the above without your consent. You must provide notice
of the existence of the Good Reason condition within thirty (30) days of the date you learn of the condition, and the Company shall have
a period of thirty (30) days during which it may remedy the condition, and in case of full remedy such condition shall not be deemed to
constitute Good Reason hereunder.
| Payment: |
By one or a combination of the following items (described in the Option Agreement): |
| |
|
|
| |
¨ |
By cash, check, bank draft or money
order payable to the Company |
| |
¨ |
Pursuant
to a Regulation T Program if the Shares are publicly traded |
| |
¨ |
By delivery of already-owned Shares
if the Shares are publicly traded |
¨ If and only to the extent this option is a Nonstatutory Share Option, and subject to the Company’s consent at the time of exercise, by a “net exercise” arrangement
Additional Terms/Acknowledgements: Optionholder
acknowledges receipt of, and understands and agrees to, this Share Option Grant Notice, the Option Agreement and the Plan. Optionholder
acknowledges and agrees that this Share Option Grant Notice and the Option Agreement may not be modified, amended or revised except as
provided in the Plan. Optionholder further acknowledges that as of the Date of Grant, this Share Option Grant Notice, the Option Agreement,
and the Plan set forth the entire understanding between Optionholder and the Company regarding this option award and supersede all prior
oral and written agreements, promises and/or representations on that subject with the exception of, if applicable, (i) equity awards
previously granted and delivered to Optionholder, (ii) any compensation recovery policy that is adopted by the Company or is otherwise
required by applicable law and (iii) any written employment agreement, severance agreement, offer letter or other written agreement
entered into between the Company and Optionholder specifying the terms that should govern this specific option. By accepting this option,
Optionholder consents to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic
system established and maintained by the Company or another third party designated by the Company.
| VYNE Therapeutics Inc. |
|
Optionholder: |
| |
|
|
| By: |
|
|
|
| Signature |
|
Signature |
| |
|
|
| Title: |
|
|
|
Attachments:
Option Agreement, 2024 Inducement Plan and Notice of Exercise
Attachment
I
VYNE
Therapeutics Inc.
Option
Agreement
(2024
Inducement Plan)
(Nonstatutory Share Option)
Pursuant to your Share Option
Grant Notice (“Grant Notice”) and this Option Agreement, VYNE Therapeutics Inc. (formerly Menlo Therapeutics
Inc.) (the “Company”) has granted you an option under its 2024 Inducement Plan (the “Plan”)
to purchase the number of Shares indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted
to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”). If there is any
conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly
defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan.
The details of your option,
in addition to those set forth in the Grant Notice and the Plan, are as follows:
1. Vesting.
Subject to the provisions contained herein, your option will vest as provided in your Grant Notice. Except as otherwise provided in the
Grant Notice, vesting will cease upon the termination of your Continuous Service.
2. Number
of Shares and Exercise Price. The number of Shares subject to your option and your exercise price per Share in your Grant Notice
will be adjusted for Capitalization Adjustments.
3. Exercise
Restriction for Non-Exempt Employees. If you are an Employee eligible for overtime compensation under the Fair Labor Standards
Act of 1938, as amended (that is, a “Non-Exempt Employee”), and except as otherwise provided in the Plan, you
may not exercise your option until you have completed at least six (6) months of Continuous Service measured from the Date of Grant,
even if you have already been an employee for more than six (6) months. Consistent with the provisions of the Worker Economic Opportunity
Act, you may exercise your option as to any vested portion prior to such six (6) month anniversary in the case of (i) your death
or disability, (ii) a Corporate Transaction in which your option is not assumed, continued or substituted, (iii) a Change in
Control or (iv) your termination of Continuous Service on your “retirement” (as defined in the Company’s benefit
plans).
4. Method
of Payment. You must pay the full amount of the exercise price for the Shares you wish to exercise. You may pay the exercise
price in cash or by check, bank draft or money order payable to the Company or in any other manner permitted by your Grant Notice,
which may include one or more of the following:
(a) Provided
that at the time of exercise Shares are publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal
Reserve Board that, prior to the issuance of Shares, results in either the receipt of cash (or check) by the Company or the receipt of
irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known
as a “broker-assisted exercise”, “same day sale”, or “sell to cover”.
(b) Provided
that at the time of exercise the Shares are publicly traded, by delivery to the Company (either by actual delivery or attestation) of
already-owned Shares that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair
Market Value on the date of exercise. “Delivery” for these purposes, in the sole discretion of the Company at the time you
exercise your option, will include delivery to the Company of your attestation of ownership of Shares in a form approved by the Company.
You may not exercise your option by delivery to the Company of Shares if doing so would violate the provisions of any law, regulation
or agreement restricting the redemption of the Company’s Shares.
(c) If
this option is a Nonstatutory Share Option, subject to the consent of the Company at the time of exercise, by a “net exercise”
arrangement pursuant to which the Company will reduce the number of Shares issued upon exercise of your option by the largest whole number
of Shares with a Fair Market Value that does not exceed the aggregate exercise price. You must pay any remaining balance of the aggregate
exercise price not satisfied by the “net exercise” in cash or other permitted form of payment. Shares will no longer be outstanding
under your option and will not be exercisable thereafter if those Shares (i) are used to pay the exercise price pursuant to the “net
exercise,” (ii) are delivered to you as a result of such exercise, and (iii) are withheld to satisfy your tax withholding
obligations.
5. Whole
Shares. You may exercise your option only for whole Shares.
6. Securities
Law Compliance. In no event may you exercise your option unless the Shares issuable upon exercise are then registered under
the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the Shares would be exempt
from the registration requirements of the Securities Act. The exercise of your option also must comply with all other applicable laws
and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be
in material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg.
1.401(k)-1(d)(3), if applicable).
7. Term.
You may not exercise your option before the Date of Grant or after the expiration of the option’s term. The term of your option
expires, subject to the provisions of Section 5(h) of the Plan, upon the earliest of the following:
(a) immediately
upon the termination of your Continuous Service for Cause;
(b) three
(3) months after the termination of your Continuous Service for any reason other than Cause, your Disability or your death; provided,
however, that if during any part of such three (3) month period your option is not exercisable solely because of the condition
set forth in the section above regarding “Securities Law Compliance,” your option will not expire until the earlier of the
Expiration Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous
Service; provided further, if during any part of such three (3) month period, the sale of any Shares received upon exercise
of your option would violate the Company’s insider trading policy, then your option will not expire until the earlier of the Expiration
Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service
during which the sale of the Shares received upon exercise of your option would not be in violation of the Company’s insider trading
policy. Notwithstanding the foregoing, if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within
six (6) months after the Date of Grant, and (iii) you have vested in a portion of your option at the time of your termination
of Continuous Service, your option will not expire until the earlier of (x) the later of (A) the date that is seven (7) months
after the Date of Grant, and (B) the date that is three (3) months after the termination of your Continuous Service, and (y) the
Expiration Date;
(c) twelve
(12) months after the termination of your Continuous Service due to your Disability (except as otherwise provided in Section 7(d))
below;
(d) eighteen
(18) months after your death if you die either during your Continuous Service or within three (3) months after your Continuous Service
terminates for any reason other than Cause;
(e) the
Expiration Date indicated in your Grant Notice; or
(f) the
day before the tenth (10th) anniversary of the Date of Grant.
8. Exercise.
(a) You
may exercise the vested portion of your option (and the unvested portion of your option if your Grant Notice so permits) during its term
by (i) delivering a Notice of Exercise (in a form designated by the Company) or completing such other documents and/or procedures
designated by the Company for exercise and (ii) paying the exercise price and any applicable withholding taxes to the Company’s
Secretary, share plan administrator, or such other person as the Company may designate, together with such additional documents as the
Company may then require.
(b) By
exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement
providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i) the exercise
of your option, (ii) the lapse of any substantial risk of forfeiture to which the Shares are subject at the time of exercise, or
(iii) the disposition of Shares acquired upon such exercise.
9. Transferability.
Except as otherwise provided in this Section 9, your option is not transferable, except by will or by the laws of descent
and distribution, and is exercisable during your life only by you.
(a) Certain
Trusts. Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option to a trust
if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while
the option is held in the trust. You and the trustee must enter into transfer and other agreements required by the Company.
(b) Domestic
Relations Orders. Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the
designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the
terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by
Treasury Regulation 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer. You are encouraged
to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order or marital
settlement agreement to help ensure the required information is contained within the domestic relations order or marital settlement agreement.
(c) Beneficiary
Designation. Upon receiving written permission from the Board or its duly authorized designee, you may, by delivering written notice
to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third
party who, on your death, will thereafter be entitled to exercise this option and receive the Shares or other consideration resulting
from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise
this option and receive, on behalf of your estate, the Shares or other consideration resulting from such exercise.
10. Option
not a Service Contract. Your option is not an employment or service contract, and nothing in your option will be deemed to
create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or
an Affiliate to continue your employment. In addition, nothing in your option will obligate the Company or an Affiliate, their respective
shareholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant
for the Company or an Affiliate.
11. Withholding
Obligations.
(a) At
the time you exercise your option, in whole or in part, and at any time thereafter as requested by the Company, you hereby authorize withholding
from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a “same
day sale” pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted
by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate,
if any, which arise in connection with the exercise of your option.
(b) If
this option is a Nonstatutory Share Option, then upon your request and subject to approval by the Company, and compliance with any applicable
legal conditions or restrictions, the Company may withhold from fully vested Shares otherwise issuable to you upon the exercise of your
option a number of whole Shares having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the
maximum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of your option
as a liability for financial accounting purposes). Notwithstanding the filing of such election, Shares shall be withheld solely from fully
vested Shares determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse
consequences to you arising in connection with such share withholding procedure shall be your sole responsibility.
(c) You
may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly, you
may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue
a certificate for such Shares or release such Shares from any escrow provided for herein, if applicable, unless such obligations are satisfied.
12. Tax
Consequences. You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation
programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors,
Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge
that this option is exempt from Section 409A of the Code only if the exercise price per Share specified in the Grant Notice is at
least equal to the “fair market value” per Share on the Date of Grant and there is no other impermissible deferral of compensation
associated with the option.
13. Notices.
Any notices provided for in your option or the Plan will be given in writing (including electronically) and will be deemed effectively
given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United
States mail, postage prepaid, addressed to you at the last address you provided to the Company. The Company may, in its sole discretion,
decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to
participate in the Plan by electronic means. By accepting this option, you consent to receive such documents by electronic delivery and
to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated
by the Company.
14. Governing
Plan Document. Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of
your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated
and adopted pursuant to the Plan. If there is any conflict between the provisions of your option and those of the Plan, the provisions
of the Plan will control. In addition, your option (and any compensation paid or Shares issued under your option) is subject to recoupment
in accordance with The Dodd–Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any
clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable law.
15. Other
Documents. You hereby acknowledge receipt of and the right to receive a document providing the information required by Rule 428(b)(1) promulgated
under the Securities Act, which includes the Plan prospectus. In addition, you acknowledge receipt of the Company’s policy permitting
certain individuals to sell Shares only during certain “window” periods and the Company’s insider trading policy, in
effect from time to time.
16. Effect
on Other Employee Benefit Plans. The value of this option will not be included as compensation, earnings, salaries, or other
similar terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as
such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company’s
or any Affiliate’s employee benefit plans.
17. Voting
Rights. You will not have voting or any other rights as a shareholder of the Company with respect to the Shares to be issued
pursuant to this option until such Shares are issued to you. Upon such issuance, you will obtain full voting and other rights as a shareholder
of the Company. Nothing contained in this option, and no action taken pursuant to its provisions, will create or be construed to create
a trust of any kind or a fiduciary relationship between you and the Company or any other person.
18. Severability.
If all or any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid,
such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid.
Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed
in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining
lawful and valid.
19. Miscellaneous.
(a) The
rights and obligations of the Company under your option will be transferable to any one or more persons or entities, and all covenants
and agreements hereunder will inure to the benefit of, and be enforceable by the Company’s successors and assigns.
(b) You
agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to
carry out the purposes or intent of your option.
(c) You
acknowledge and agree that you have reviewed your option in its entirety, have had an opportunity to obtain the advice of counsel prior
to executing and accepting your option, and fully understand all provisions of your option.
(d) This
Option Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or
national securities exchanges as may be required.
(e) All
obligations of the Company under the Plan and this Option Agreement will be binding on any successor to the Company, whether the existence
of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of
the business and/or assets of the Company.
* * *
This Option Agreement will
be deemed to be signed by you upon the signing by you of the Share Option Grant Notice to which it is attached.
Attachment
II
2024
Inducement Plan
Attachment
III
Notice
of Exercise
VYNE
Therapeutics Inc.
Date of Exercise: _______________
This constitutes notice to
VYNE Therapeutics Inc. (the “Company”) under my share option that I elect to purchase the below number of shares
of common stock of the Company (the “Shares”) for the price set forth below.
| Type of option (check one): |
Nonstatutory |
|
| |
|
|
| Share option dated: |
_______________ |
|
| |
|
|
| Number of Shares as to which option is exercised: |
_______________ |
|
| |
|
|
| Certificates to be issued in name of: |
_______________ |
|
| |
|
|
| Total exercise price: |
$______________ |
|
| |
|
|
| Cash payment delivered herewith: |
$______________ |
|
| |
|
|
| [Value of ________ Shares delivered herewith1: |
$______________ |
|
| |
|
|
| [Value of ________ Shares pursuant to net exercise2: |
$______________ |
|
| |
|
|
| [Regulation T Program (cashless exercise3): |
$______________ |
|
1
Shares must meet the public trading requirements set forth in the
option. Shares must be valued in accordance with the terms of the option being exercised, and must be owned free and clear of any liens,
claims, encumbrances or security interests. Certificates must be endorsed or accompanied by an executed assignment separate from certificate.
2 The
Company must have established net exercise procedures at the time of exercise, in order to utilize this payment method.
3
Shares must meet the public trading requirements set forth in the
option.
By this exercise, I agree
(i) to provide such additional documents as you may require pursuant to the terms of the VYNE Therapeutics Inc. 2024 Inducement Plan
and (ii) to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating
to the exercise of this option.
Exhibit 4.6
VYNE
Therapeutics Inc.
Restricted
Share Unit Grant Notice
(2024 Inducement Plan)
VYNE Therapeutics Inc. (formerly Menlo Therapeutics Inc.) (the “Company”),
pursuant to its 2024 Inducement Plan (the “Plan”), hereby awards to Participant a Restricted Share Unit Award
for the number of Shares (“Restricted Share Units”) set forth below (the “Award”).
The Award is subject to all of the terms and conditions as set forth in this notice of grant (this “Restricted Share Unit
Grant Notice”), and in the Plan and the Restricted Share Unit Award Agreement (the “Award Agreement”),
both of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein shall have
the meanings set forth in the Plan or the Award Agreement. In the event of any conflict between the terms in this Restricted Share Unit
Grant Notice or the Award Agreement and the Plan, the terms of the Plan shall control.
| Participant: |
|
| Date of Grant: |
|
| Vesting Commencement Date: |
|
| Number of Restricted Share Units: |
|
Vesting Schedule:
[insert], subject to the Participant’s Continuous Service with
the Company as of each such vesting date; provided however, that the Restricted Share Units shall vest in full upon a termination of the
Participant’s Continuous Service (i) by the Company without Cause (as defined in the Plan) or (ii) upon a resignation
by the Participant for Good Reason (as defined in the applicable written agreement between the Participant and the Company; provided that
if no such definition is included in a written agreement between the Participant and the Company, “Good Reason” shall have
the meaning set forth below), in each case, within 12 months following a Change in Control.
“Good Reason” means: (i) a material reduction
in your base salary; (ii) a material reduction in your target annual bonus opportunity; (iii) a relocation of your principal
place of employment by more than twenty-five (25) miles; or (iv) an adverse change in your position, including title, reporting relationship(s),
authority, duties or responsibilities; all of the above without your consent. You must provide notice of the existence of the Good Reason
condition within thirty (30) days of the date you learn of the condition, and the Company shall have a period of thirty (30) days during
which it may remedy the condition, and in case of full remedy such condition shall not be deemed to constitute Good Reason hereunder.
| Issuance Schedule: |
Subject to any Capitalization Adjustment, one Share (or its cash equivalent, at the discretion of the Company) will be issued for each
Restricted Share Unit that vests at the time set forth in Section 6 of the Award Agreement. |
Additional
Terms/Acknowledgements: Participant acknowledges receipt of, and understands and agrees to, this Restricted Share Unit Grant
Notice, the Award Agreement and the Plan. Participant further acknowledges that as of the Date of Grant, this Restricted Share Unit Grant
Notice, the Award Agreement and the Plan set forth the entire understanding between Participant and the Company regarding the acquisition
of the Share pursuant to the Award specified above and supersede all prior oral and written agreements on the terms of this Award, with
the exception, if applicable, of (i) restricted share unit awards or options previously granted and delivered to Participant, (ii) the
written employment agreement, offer letter or other written agreement entered into between the Company and Participant specifying the
terms that should govern this specific Award, and (iii) any compensation recovery policy that is adopted by the Company or is otherwise
required by applicable law.
By accepting this Award, Participant acknowledges having received and
read the Restricted Share Unit Grant Notice, the Award Agreement and the Plan and agrees to all of the terms and conditions set forth
in these documents. Participant consents to receive Plan documents by electronic delivery and to participate in the Plan through an on-line
or electronic system established and maintained by the Company or another third party designated by the Company.
| VYNE Therapeutics Inc. |
|
Participant |
| |
|
|
| By: |
|
|
|
| Signature |
|
Signature |
| |
|
|
| Title: |
|
|
|
| Attachments: | Award Agreement and 2024 Inducement Plan |
Attachment
I
VYNE
Therapeutics Inc.
2024
Inducement Plan
Restricted
Share Unit Award Agreement
Pursuant to the Restricted
Share Unit Grant Notice (the “Grant Notice”) and this Restricted Share Unit Award Agreement (the “Agreement”),
VYNE Therapeutics Inc. (formerly Menlo Therapeutics Inc.) (the “Company”) has awarded you (“Participant”)
a Restricted Share Unit Award (the “Award”) pursuant to the Company’s 2024 Inducement Plan (the “Plan”)
for the number of Restricted Share Units/Shares indicated in the Grant Notice. Capitalized terms not explicitly defined in this Agreement
or the Grant Notice shall have the same meanings given to them in the Plan. The terms of your Award, in addition to those set forth in
the Grant Notice, are as follows.
1. Grant
of the Award. This Award represents the right to be issued on a future date one (1) Share for each Restricted Share Unit
that vests on the applicable vesting date(s) (subject to any adjustment under Section 3 below) as indicated in the Grant Notice.
As of the Date of Grant, the Company will credit to a bookkeeping account maintained by the Company for your benefit (the “Account”)
the number of Restricted Share Units/Shares subject to the Award. Notwithstanding the foregoing, the Company reserves the right to issue
you the cash equivalent of Shares, in part or in full satisfaction of the delivery of Shares in connection with the vesting of the Restricted
Share Units, and, to the extent applicable, references in this Agreement and the Grant Notice to Share issuable in connection with your
Restricted Share Units will include the potential issuance of its cash equivalent pursuant to such right. This Award was granted in consideration
of your services to the Company.
2. Vesting.
Subject to the limitations contained herein, your Award will vest, if at all, in accordance with the vesting schedule provided
in the Grant Notice. Except as otherwise provided in the Grant Notice, vesting will cease upon the termination of your Continuous Service
and the Restricted Share Units credited to the Account that were not vested on the date of such termination will be forfeited at no cost
to the Company and you will have no further right, title or interest in or to such Award or the Shares to be issued in respect of such
portion of the Award.
3. Number
of Shares. The number of Restricted Share Units subject to your Award may be adjusted from time to time for Capitalization
Adjustments, as provided in the Plan. Any additional Restricted Share Units, Shares, cash or other property that becomes subject to the
Award pursuant to this Section 3, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions,
restrictions on transferability, and time and manner of delivery as applicable to the other Restricted Share Units and Shares covered
by your Award. Notwithstanding the provisions of this Section 3, no fractional Shares or rights for fractional Shares shall be created
pursuant to this Section 3. Any fraction of a Share will be rounded down to the nearest whole Share.
4. Securities
Law Compliance. You may not be issued any Shares under your Award unless the Shares underlying the Restricted Share Units are
either (i) then registered under the Securities Act, or (ii) the Company has determined that such issuance would be exempt from
the registration requirements of the Securities Act. Your Award must also comply with other applicable laws and regulations governing
the Award, and you shall not receive such Shares if the Company determines that such receipt would not be in material compliance with
such laws and regulations.
5. Transfer
Restrictions. Prior to the time that Shares have been delivered to you, you may not transfer, pledge, sell or otherwise dispose
of this Award or the Shares issuable in respect of your Award, except as expressly provided in this Section 5. For example, you may
not use Shares that may be issued in respect of your Restricted Share Units as security for a loan. The restrictions on transfer set forth
herein will lapse upon delivery to you of Shares in respect of your vested Restricted Share Units.
(a) Death.
Your Award is transferable by will and by the laws of descent and distribution. At your death, vesting of your Award will cease and your
executor or administrator of your estate shall be entitled to receive, on behalf of your estate, any Shares or other consideration that
vested but was not issued before your death.
(b) Domestic
Relations Orders. Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the
designated transferee enter into transfer and other agreements required by the Company, you may transfer your right to receive the distribution
of Shares or other consideration hereunder, pursuant to a domestic relations order, marital settlement agreement or other divorce or separation
instrument as permitted by applicable law that contains the information required by the Company to effectuate the transfer. You are encouraged
to discuss the proposed terms of any division of this Award with the Company General Counsel prior to finalizing the domestic relations
order or marital settlement agreement to verify that you may make such transfer, and if so, to help ensure the required information is
contained within the domestic relations order or marital settlement agreement.
6. Date
of Issuance.
(a) The
issuance of Shares in respect of the Restricted Share Units is intended to comply with Treasury Regulations Section 1.409A-1(b)(4) and
will be construed and administered in such a manner. Subject to the satisfaction of the Withholding Obligation set forth in Section 11
of this Agreement, in the event one or more Restricted Share Units vests, the Company shall issue to you one (1) Share for each Restricted
Share Unit that vests on the applicable vesting date(s) (subject to any adjustment under Section 3 above, and subject to any
different provisions in the Grant Notice). Each issuance date determined by this paragraph is referred to as an “Original
Issuance Date”.
(b) If
the Original Issuance Date falls on a date that is not a business day, delivery shall instead occur on the next following business day.
In addition, if:
(i) the
Original Issuance Date does not occur (1) during an “open window period” applicable to you, as determined by the Company
in accordance with the Company’s then-effective policy on trading in Company securities, or (2) on a date when you are otherwise
permitted to sell Shares on an established stock exchange or stock market (including but not limited to under a previously established
written trading plan that meets the requirements of Rule 10b5-1 under the Exchange Act and was entered into in compliance with the
Company's policies (a “10b5-1 Arrangement”)), and
(ii) either
(1) a Withholding Obligation does not apply, or (2) the Company decides, prior to the Original Issuance Date, (A) not to
satisfy the Withholding Obligation by withholding Shares from the Shares otherwise due, on the Original Issuance Date, to you under this
Award, and (B) not to permit you to enter into a “same day sale” commitment with a broker-dealer pursuant to Section 11
of this Agreement (including but not limited to a commitment under a 10b5-1 Arrangement) and (C) not to permit you to pay your Withholding
Obligation in cash,
then
the Shares that would otherwise be issued to you on the Original Issuance Date will not be delivered on such Original Issuance Date and
will instead be delivered on the first business day when you are not prohibited from selling Shares in the open public market, but in
no event later than December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of your taxable
year in which the Original Issuance Date occurs), or, if and only if permitted in a manner that complies with Treasury Regulations
Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the applicable year following
the year in which the Shares under this Award are no longer subject to a “substantial risk of forfeiture” within the meaning
of Treasury Regulations Section 1.409A-1(d).
(c) The
form of delivery (e.g., a Share certificate or electronic entry evidencing such Shares) shall be determined by the Company.
7. Dividends.
You shall receive no benefit or adjustment to your Award with respect to any cash dividend, share dividend or other distribution that
does not result from a Capitalization Adjustment; provided, however, that this sentence will not apply with respect to any Shares that
are delivered to you in connection with your Award after such Shares have been delivered to you.
8. Restrictive
Legends. The Shares issued in respect of your Award shall be endorsed with appropriate legends as determined by the Company.
9. Execution
of Documents. You hereby acknowledge and agree that the manner selected by the Company by which you indicate your consent to
your Grant Notice is also deemed to be your execution of your Grant Notice and of this Agreement. You further agree that such manner of
indicating consent may be relied upon as your signature for establishing your execution of any documents to be executed in the future
in connection with your Award.
10. Award
not a Service Contract.
(a) Nothing
in this Agreement (including, but not limited to, the vesting of your Award or the issuance of the Shares in respect of your Award), the
Plan or any covenant of good faith and fair dealing that may be found implicit in this Agreement or the Plan shall: (i) confer upon
you any right to continue in the employ or service of, or affiliation with, the Company or an Affiliate; (ii) constitute any promise
or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation
or any other term or condition of employment or affiliation; (iii) confer any right or benefit under this Agreement or the Plan unless
such right or benefit has specifically accrued under the terms of this Agreement or Plan; or (iv) deprive the Company of the right
to terminate you at will and without regard to any future vesting opportunity that you may have.
(b) By
accepting this Award, you acknowledge and agree that the right to continue vesting in the Award pursuant to the vesting schedule provided
in the Grant Notice may not be earned unless (in addition to any other conditions described in the Grant Notice and this Agreement) you
continue as an employee, director or consultant at the will of the Company and affiliate, as applicable (not through the act of being
hired, being granted this Award or any other award or benefit) and that the Company has the right to reorganize, sell, spin-out or otherwise
restructure one or more of its businesses or Affiliates at any time or from time to time, as it deems appropriate (a “reorganization”).
You acknowledge and agree that such a reorganization could result in the termination of your Continuous Service, or the termination of
Affiliate status of your employer and the loss of benefits available to you under this Agreement, including but not limited to, the termination
of the right to continue vesting in the Award. You further acknowledge and agree that this Agreement, the Plan, the transactions contemplated
hereunder and the vesting schedule set forth herein or any covenant of good faith and fair dealing that may be found implicit in any of
them do not constitute an express or implied promise of continued engagement as an employee or consultant for the term of this Agreement,
for any period, or at all, and shall not interfere in any way with the Company’s right to terminate your Continuous Service at any
time, with or without your cause or notice, or to conduct a reorganization.
11. Withholding
Obligation.
(a) On
each vesting date, and on or before the time you receive a distribution of the Shares in respect of your Restricted Share Units, and at
any other time as reasonably requested by the Company in accordance with applicable tax laws, you hereby authorize any required withholding
from the Share issuable to you and/or otherwise agree to make adequate provision, including in cash, for any sums required to satisfy
the federal, state, local and foreign tax withholding obligations of the Company or any Affiliate that arise in connection with your Award
(the “Withholding Obligation”).
(b) By
accepting this Award, you acknowledge and agree that the Company or any Affiliate may, in its sole discretion, satisfy all or any portion
of the Withholding Obligation relating to your Restricted Share Units by any of the following means or by a combination of such means:
(i) causing you to pay any portion of the Withholding Obligation in cash; (ii) withholding from any compensation otherwise payable
to you by the Company; (iii) withholding Shares from the Shares issued or otherwise issuable to you in connection with the Award
with a Fair Market Value (measured as of the date Shares are issued pursuant to Section 6) equal to the amount of such Withholding
Obligation; provided, however, that the number of such Shares so withheld will not exceed the amount necessary to satisfy the Withholding
Obligation using the maximum statutory withholding rates for federal, state, local and foreign tax purposes, including payroll taxes,
that are applicable to supplemental taxable income; and provided, further, that to the extent necessary to qualify for an exemption
from application of Section 16(b) of the Exchange Act, if applicable, such Share withholding procedure will be subject to the
express prior approval of the Board or the Company’s Compensation Committee; and/or (iv) permitting or requiring you to enter
into a “same day sale” commitment, if applicable, with a broker-dealer that is a member of the Financial Industry Regulatory
Authority (a “FINRA Dealer”), pursuant to this authorization and without further consent, whereby you irrevocably
elect to sell a portion of the Shares to be delivered in connection with your Restricted Share Units to satisfy the Withholding Obligation
and whereby the FINRA Dealer irrevocably commits to forward the proceeds necessary to satisfy the Withholding Obligation directly to the
Company and/or its Affiliates. Unless the Withholding Obligation is satisfied, the Company shall have no obligation to deliver to you
any Share or any other consideration pursuant to this Award.
(c) In
the event the Withholding Obligation arises prior to the delivery to you of Share or it is determined after the delivery of Share to you
that the amount of the Withholding Obligation was greater than the amount withheld by the Company, you agree to indemnify and hold the
Company harmless from any failure by the Company to withhold the proper amount.
12. Tax
Consequences. The Company has no duty or obligation to minimize the tax consequences to you of this Award and shall not be
liable to you for any adverse tax consequences to you arising in connection with this Award. You are hereby advised to consult with your
own personal tax, financial and/or legal advisors regarding the tax consequences of this Award and by signing the Grant Notice, you have
agreed that you have done so or knowingly and voluntarily declined to do so. You understand that you (and not the Company) shall be responsible
for your own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement.
13. Unsecured
Obligation. Your Award is unfunded, and as a holder of a vested Award, you shall be considered an unsecured creditor of the
Company with respect to the Company’s obligation, if any, to issue Shares or other property pursuant to this Agreement. You shall
not have voting or any other rights as a shareholder of the Company with respect to the Shares to be issued pursuant to this Agreement
until such Shares are issued to you pursuant to Section 6 of this Agreement. Upon such issuance, you will obtain full voting and
other rights as a shareholder of the Company. Nothing contained in this Agreement, and no action taken pursuant to its provisions, shall
create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.
14. Notices.
Any notice or request required or permitted hereunder shall be given in writing (including electronically)
and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days
after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. The Company
may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this Award by electronic means or
to request your consent to participate in the Plan by electronic means. By accepting this Award, you consent to receive such documents
by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company
or another third party designated by the Company.
15. Headings.
The headings of the Sections in this Agreement are inserted for convenience only and shall not be deemed to constitute a part of this
Agreement or to affect the meaning of this Agreement.
16. Miscellaneous.
(a) The
rights and obligations of the Company under your Award shall be transferable by the Company to any one or more persons or entities, and
all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by, the Company’s successors and assigns.
(b) You
agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to
carry out the purposes or intent of your Award.
(c) You
acknowledge and agree that you have reviewed your Award in its entirety, have had an opportunity to obtain the advice of counsel prior
to executing and accepting your Award and fully understand all provisions of your Award.
(d) This
Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national
securities exchanges as may be required.
(e) All
obligations of the Company under the Plan and this Agreement shall be binding on any successor to the Company, whether the existence of
such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the
business and/or assets of the Company.
17. Governing
Plan Document. Your Award is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your
Award, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated
and adopted pursuant to the Plan. Your Award (and any compensation paid or Shares issued under your Award) is subject to recoupment in
accordance with The Dodd–Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback
policy adopted by the Company and any compensation recovery policy otherwise required by applicable law. No recovery of compensation under
such a clawback policy will be an event giving rise to a right to voluntarily terminate employment upon a resignation for “good
reason,” or for a “constructive termination” or any similar term under any plan of or agreement with the Company.
18. Effect
on Other Employee Benefit Plans. The value of the Award subject to this Agreement shall not be included as compensation, earnings,
salaries, or other similar terms used when calculating benefits under any employee benefit plan (other than the Plan) sponsored by the
Company or any Affiliate except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify,
or terminate any or all of the employee benefit plans of the Company or any Affiliate.
19. Severability.
If all or any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness
or invalidity shall not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid. Any Section of
this Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will
give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.
20. Other
Documents. You hereby acknowledge receipt or the right to receive a document providing the information required by Rule 428(b)(1) promulgated
under the Securities Act. In addition, you acknowledge receipt of the Company’s policy permitting certain individuals to sell Shares
only during certain "window" periods and the Company's insider trading policy, in effect from time to time.
21. Amendment.
This Agreement may not be modified, amended or terminated except by an instrument in writing, signed by you and by a duly authorized representative
of the Company. Notwithstanding the foregoing, this Agreement may be amended solely by the Board by a writing which specifically states
that it is amending this Agreement, so long as a copy of such amendment is delivered to you, and provided that, except as otherwise expressly
provided in the Plan, no such amendment materially adversely affecting your rights hereunder may be made without your written consent.
Without limiting the foregoing, the Board reserves the right to change, by written notice to you, the provisions of this Agreement in
any way it may deem necessary or advisable to carry out the purpose of the Award as a result of any change in applicable laws or regulations
or any future law, regulation, ruling, or judicial decision, provided that any such change shall be applicable only to rights relating
to that portion of the Award which is then subject to restrictions as provided herein.
22. Compliance
with Section 409A of the Code. This Award is intended to be exempt from the application of Section 409A of
the Code, including but not limited to by reason of complying with the “short-term deferral” rule set forth in Treasury
Regulation Section 1.409A-1(b)(4) and any ambiguities herein shall be interpreted accordingly. Notwithstanding the foregoing,
if it is determined that the Award fails to satisfy the requirements of the short-term deferral rule and is otherwise not exempt
from, and determined to be deferred compensation subject to Section 409A of the Code, this Award shall comply with Section 409A
to the extent necessary to avoid adverse personal tax consequences and any ambiguities herein shall be interpreted accordingly. If it
is determined that the Award is deferred compensation subject to Section 409A and you are a “Specified Employee” (within
the meaning set forth in Section 409A(a)(2)(B)(i) of the Code) as of the date of your “Separation from Service”
(as defined in Section 409A), then the issuance of any Shares that would otherwise be made upon the date of your Separation from
Service or within the first six (6) months thereafter will not be made on the originally scheduled date(s) and will instead
be issued in a lump sum on the date that is six (6) months and one day after the date of the Separation from Service, with the balance
of the Shares issued thereafter in accordance with the original vesting and issuance schedule set forth above, but if and only if such
delay in the issuance of the Shares is necessary to avoid the imposition of adverse taxation on you in respect of the Shares under Section 409A
of the Code. Each installment of Shares that vests is intended to constitute a “separate payment” for purposes of Treasury
Regulation Section 1.409A-2(b)(2).
* * * * *
This Restricted Share Unit
Award Agreement shall be deemed to be signed by the Company and the Participant upon the signing by the Participant of the Restricted
Share Unit Grant Notice to which it is attached.
Attachment
II
2024
Inducement Plan
Exhibit 5.1
Mark D. Ballantyne
T:
+1 703 456 8084
mballantyne@cooley.com
March 1, 2024
VYNE Therapeutics Inc.
685 Route 202/206 N., Suite 301
Bridgewater, New Jersey 08807
Ladies and Gentlemen,
We have acted as counsel
to VYNE Therapeutics Inc., a Delaware corporation (the “Company”), in connection with the filing by the
Company of a Registration Statement on Form S-8 (the “Registration Statement”) with the Securities
and Exchange Commission (the “Commission”) covering the offering of up to 500,000 shares (the “Shares”)
of the Company’s common stock, par value $0.0001 per share, pursuant to the Company’s 2024 Inducement Plan (the “Plan”).
In connection with this
opinion, we have examined and relied upon (a) the Registration Statement and the related prospectus, (b) the Company’s
certificate of incorporation and bylaws, each as currently in effect, (c) the Plan and (d) such other records, documents, opinions,
certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed
below.
We have assumed the genuineness
of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted
to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution
and delivery of all documents by all persons other than the Company where authorization, execution and delivery are prerequisites to the
effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently
verified such matters.
Our opinion is expressed
only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are
applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities
law, rule or regulation.
On the basis of the foregoing,
and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plan, the Registration Statement
and the related prospectus, will be validly issued, fully paid and nonassessable (except as to shares issued pursuant to deferred payment
arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).
This opinion is limited
to the matters expressly set forth in this letter, and no opinion should be implied, or may be inferred, beyond the matters expressly
stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof and we have no obligation or responsibility
to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in
law that may hereafter occur.
We consent to the filing of this opinion as
an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose
consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission
thereunder.
Cooley LLP Reston Town Center 11951 Freedom Drive 14th Floor Reston, VA 20190-5656
t: +1 703 456 8000 f: +1 703 456 8100 cooley.com
March 1, 2024
Page Two
Sincerely,
Cooley LLP
| By: |
/s/ Mark Ballantyne |
|
| |
Mark Ballantyne |
|
Cooley LLP Reston Town Center 11951 Freedom Drive 14th Floor Reston, VA 20190-5656
t: +1 703 456 8000 f: +1 703 456 8100 cooley.com
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
We hereby consent to the incorporation by reference in this Registration
Statement on Form S-8 of our report dated March 1, 2024, relating to the consolidated financial statements of VYNE Therapeutics
Inc. which appears in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.
/s/ BAKER TILLY US, LLP
Tewksbury, Massachusetts
March 1, 2024
Exhibit 107
Calculation of Filing Fee Tables
Form S-8
VYNE THERAPEUTICS
INC.
(Exact Name of Registrant as Specified in its Charter)
Security
Type |
Security
Class Title |
Fee
Calculation
Rule |
Amount
Registered |
Proposed
Maximum
Offering
Price Per
Share |
Maximum
Aggregate
Offering Price |
Fee Rate |
Amount of
Registration
Fee |
| Equity |
Common Stock, $0.0001 par value per share |
457(c)
and
457(h) |
500,000(1)(2) |
$2.25(3) |
$1,125,000(3) |
0.00014760 |
$166.05 |
| Total Offering Amounts |
|
$1,125,000 |
|
$166.05 |
| Total Fee Offsets |
|
|
|
– |
| Net Fee Due |
|
|
|
$166.05 |
| (1) |
In accordance with Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall be deemed to cover any additional shares of common stock, par value $0.0001 per share (“Shares”), of VYNE Therapeutics Inc. (the “Registrant”) that become issuable under the Registrant’s 2024 Inducement Plan (the “Inducement Plan”) by reason of any stock dividend, stock split, recapitalization or other similar transaction. |
| |
|
| (2) |
Represents the maximum number of Shares reserved for issuance under the Inducement Plan. |
| |
|
| (3) |
Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended. The proposed maximum offering price per share and aggregate offering price are calculated on the basis of $2.25, the average of the high and low price of the Registrant’s Shares as reported on the Nasdaq Capital Market on February 29, 2024. |
Grafico Azioni VYNE Therapeutics (NASDAQ:VYNE)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni VYNE Therapeutics (NASDAQ:VYNE)
Storico
Da Nov 2023 a Nov 2024
